AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Calcium phosphate nanoparticles (CAP) acted as a potent adjuvant in the mucosal delivery of a vaccine directed against of herpes simplex virus type 2 (HSV-2) in mice, according to a report in Clinical and Diagnostic Laboratory Immunology.
Qing He and colleagues at BioSante Pharmaceuticals, Inc., in Smyrna, Georgia, in the U.S. expanded on earlier research that demonstrated CAP was a better choice than alum as an adjuvant for antiviral vaccines. Previous studies showed that CAP was safe and did not stimulate a detectable IgE response.
In the present report, He and associates show that CAP enhances systemic immunity after mucosal delivery of a vaccine containing HSV-2 antigen plus CAP.
The investigators immunized mice intravaginally and intranasally with one of the following four vaccine formulations: HSV-2 antigen plus CAP as an adjuvant (HSV-2+CAP), CAP alone, phosphate-buffered saline (PBS) alone, or HSV-2 protein alone.
Mucosal IgA and IgG anti-HSV antibody responses and a systemic IgG antibody response occurred in the mice vaccinated with HSV-2+CAP. In vivo experiments demonstrated that mice inoculated with HSV-2+CAP were protected against a challenge with viable HSV-2.
"In conclusion, these preclinical data ...